ArticleFrontiers in physiology2025
Trimethylamine N-oxide (TMAO) acutely alters ionic currents but does not increase cardiac cell death.
Article in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- The influence of a plant-based diet on the composition and functions of the human gut microbiota: a review.Frontiers in nutrition · 2026Review
- Cardiac ventricular Kir6.1 ATP-sensitive potassium channels: an overlooked effector of cardioprotection.Frontiers in physiology · 2026Article
- From Gut to Heart: Targeting Trimethylamine N-Oxide as a Novel Strategy in Heart Failure Management.Biomolecules · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Trimethylamine N-oxide (TMAO) is a product of the action of gut microbiota on choline and other choline-containing compounds ingested in the diet. The presence of TMAO at high concentrations has been reported in the blood of patients with cardiovascular disease, suggesting the role for TMAO as either a marker or causative agent of the disease. These investigations examined whether TMAO had an effect on cardiomyocyte contractile function, calcium homoeostasis, and survival from metabolic insult. Results: TMAO had no effect on metabolic function or the ability of cells to survive a metabolic insult; however, it did cause transient changes to contractile function. These changes included an increase in calcium current and an increase in Kir6.1 channel activity in the cell, causing a shortening of the action potential duration to 90% repolarised but lengthening the action potential to 30% repolarised. These effects occurred within minutes of TMAO application; however, they were not observed following 24 h culture. These data suggest that TMAO does modulate contractile function, albeit only in the short-term, but has no effect on metabolic behaviour or the ability to withstand a metabolic challenge. Conclusion: These data suggest that high TMAO concentrations in the blood of patients may be a marker of potential cardiovascular disease rather than playing a causative role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.